183 related articles for article (PubMed ID: 15977464)
1. Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data.
Adachi JD; Rizzoli R; Boonen S; Li Z; Meredith MP; Chesnut CH
Aging Clin Exp Res; 2005 Apr; 17(2):150-6. PubMed ID: 15977464
[TBL] [Abstract][Full Text] [Related]
2. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
[TBL] [Abstract][Full Text] [Related]
3. Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Cranney A; Waldegger L; Zytaruk N; Shea B; Weaver B; Papaioannou A; Robinson V; Wells G; Tugwell P; Adachi JD; Guyatt G
Cochrane Database Syst Rev; 2003; (4):CD004523. PubMed ID: 14584020
[TBL] [Abstract][Full Text] [Related]
4. WITHDRAWN: Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Cranney A; Adachi JD; Guyatt G; Papaioannou A; Robinson VA; Shea BJ; Tugwell P; Waldegger LM; Weaver B; Wells G; Zytaruk N
Cochrane Database Syst Rev; 2007 Jul; (1):CD004523. PubMed ID: 17636764
[TBL] [Abstract][Full Text] [Related]
5. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
6. Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture.
Kanis JA; Barton IP; Johnell O
Osteoporos Int; 2005 May; 16(5):475-82. PubMed ID: 15875093
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of risedronate on clinical vertebral fractures within six months.
Roux C; Seeman E; Eastell R; Adachi J; Jackson RD; Felsenberg D; Songcharoen S; Rizzoli R; Di Munno O; Horlait S; Valent D; Watts NB
Curr Med Res Opin; 2004 Apr; 20(4):433-9. PubMed ID: 15119979
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.
Boonen S; McClung MR; Eastell R; El-Hajj Fuleihan G; Barton IP; Delmas P
J Am Geriatr Soc; 2004 Nov; 52(11):1832-9. PubMed ID: 15507059
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
Reginster J; Minne HW; Sorensen OH; Hooper M; Roux C; Brandi ML; Lund B; Ethgen D; Pack S; Roumagnac I; Eastell R
Osteoporos Int; 2000; 11(1):83-91. PubMed ID: 10663363
[TBL] [Abstract][Full Text] [Related]
10. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.
Roux C; Goldstein JL; Zhou X; Klemes A; Lindsay R
Osteoporos Int; 2012 Jan; 23(1):277-84. PubMed ID: 21365461
[TBL] [Abstract][Full Text] [Related]
11. A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.
Clemmesen B; Ravn P; Zegels B; Taquet AN; Christiansen C; Reginster JY
Osteoporos Int; 1997; 7(5):488-95. PubMed ID: 9425508
[TBL] [Abstract][Full Text] [Related]
12. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis.
Harris ST; Watts NB; Li Z; Chines AA; Hanley DA; Brown JP
Curr Med Res Opin; 2004 May; 20(5):757-64. PubMed ID: 15140343
[TBL] [Abstract][Full Text] [Related]
13. Review of risedronate in the treatment of osteoporosis.
Geusens P; McClung M
Expert Opin Pharmacother; 2001 Dec; 2(12):2011-25. PubMed ID: 11825332
[TBL] [Abstract][Full Text] [Related]
14. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
Reid DM; Adami S; Devogelaer JP; Chines AA
Calcif Tissue Int; 2001 Oct; 69(4):242-7. PubMed ID: 11730260
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
Palomba S; Orio F; Manguso F; Falbo A; Russo T; Tolino A; Tauchmanovà L; Colao A; Doldo P; Mastrantonio P; Zullo F
Osteoporos Int; 2005 Sep; 16(9):1141-9. PubMed ID: 15928801
[TBL] [Abstract][Full Text] [Related]
17. Fracture risk remains reduced one year after discontinuation of risedronate.
Watts NB; Chines A; Olszynski WP; McKeever CD; McClung MR; Zhou X; Grauer A
Osteoporos Int; 2008 Mar; 19(3):365-72. PubMed ID: 17938986
[TBL] [Abstract][Full Text] [Related]
18. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
Wallach S; Cohen S; Reid DM; Hughes RA; Hosking DJ; Laan RF; Doherty SM; Maricic M; Rosen C; Brown J; Barton I; Chines AA
Calcif Tissue Int; 2000 Oct; 67(4):277-85. PubMed ID: 11000340
[TBL] [Abstract][Full Text] [Related]
19. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
Hadji P; Zanchetta JR; Russo L; Recknor CP; Saag KG; McKiernan FE; Silverman SL; Alam J; Burge RT; Krege JH; Lakshmanan MC; Masica DN; Mitlak BH; Stock JL
Osteoporos Int; 2012 Aug; 23(8):2141-50. PubMed ID: 22159672
[TBL] [Abstract][Full Text] [Related]
20. Effects of risedronate on fracture risk in postmenopausal women with osteopenia.
Siris ES; Simon JA; Barton IP; McClung MR; Grauer A
Osteoporos Int; 2008 May; 19(5):681-6. PubMed ID: 17968610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
